Dasatinib and the Risk of Pulmonary Arterial Hypertension

Published Online: Friday, October 21, 2011
Follow Pharmacy_Times:
In this podcast, Jennifer Shepherd, a pharmacist in the FDA’s Division of Drug Information, discusses the increased risk of pulmonary arterial hypertension associated with Sprycel (dasatinib), a drug indicated to treat leukemia.

To access the podcast, click here.
Related Articles
Through the Pharmacist Connect program, pharmacists from chain member companies provided 2014 NACDS Total Store Expo attendees with immunizations and other pharmacy services.
Although many pharmacists express concerns about the state of the pharmacy job market, the good news is the demand for pharmacists seems to be increasing.
In several countries, increases in the incidence of inflammatory bowel disease have been observed closely following regulatory approval of sucralose.
Pharmacists gauge patients’ recognition of medical terms higher than doctors do.
Latest Issues
$auto_registration$